Updated: Novartis signs macrocyclic deal with Unnatural Products
更新：诺华与Unnatural Products达成大环化合物合作协议

Novartis will pay $100 million in upfront and pre-IND milestone payments to tap into a macrocyclic peptide platform from Unnatural Products, a deal that could lead to new cardiovascular disease medicines.
Novartis将向Unnatural Products支付1亿美元的预付款和IND前里程碑付款，以获取其大环肽平台的使用权，此项交易有望促成新的cardiovascular disease medicines的诞生。